Welcome to our dedicated page for Golden Arrow Merger news (Ticker: GAMC), a resource for investors and traders seeking the latest updates and insights on Golden Arrow Merger stock.
Golden Arrow Merger Corp. (GAMC) provides investors with centralized access to official news and regulatory filings related to its special purpose acquisition company (SPAC) operations. This resource aggregates press releases, SEC disclosures, and merger-related announcements to streamline due diligence for stakeholders.
Users gain immediate visibility into GAMC's merger progress, capital market activities, and corporate governance updates. The page organizes content by merger transaction developments, regulatory filings, and strategic partnership announcements, maintaining compliance-focused transparency.
Bookmark this page for structured access to GAMC's evolving SPAC narrative, including prospectus updates and acquisition target evaluations. Check regularly for verified information supporting informed analysis of the company's merger timeline and market positioning.
Bolt Threads (Nasdaq: BSLK) has completed its business combination with Golden Arrow Merger Corp (Nasdaq: GAMC), approved on August 9, 2024. The new entity, Bolt Projects Holdings, will trade on Nasdaq starting August 14, 2024, under the ticker BSLK. Led by CEO Dan Widmaier, Bolt Threads aims to scale its sustainable biomaterials platform, particularly in the beauty and personal care sectors.
The company boasts a significant intellectual property portfolio with 49 granted patents and 171 pending applications. Its flagship product, b-silk™, offers a biodegradable and non-toxic alternative to silicone elastomers in beauty products. Bolt Threads envisions substantial growth and value creation for stakeholders.
Golden Arrow Merger Corp. (NYSE: GAMCU, GAMC, GAMCW) has canceled its special meeting originally scheduled for December 16, 2022, and withdrawn the proposals set forth in its Definitive Proxy Statement filed with the SEC on November 28, 2022. The company, formed as a blank check entity, aims to pursue mergers or acquisitions, primarily targeting the healthcare sector in developed countries.
On June 4, 2021, Golden Arrow Merger Corp. announced it received a deficiency notice from Nasdaq due to its failure to file the Quarterly Report on Form 10-Q for the period ending March 31, 2021. This delay was a result of the SEC's Staff Statement on accounting considerations for warrants issued by SPACs, impacting many SPACs, including Golden Arrow. The company successfully filed its Form 10-Q by the June 4 deadline and remains compliant with Nasdaq's listing standards. Golden Arrow is focused on acquiring businesses in the healthcare sector.
Golden Arrow Merger Corp. announced the full exercise of the over-allotment option by underwriters in its IPO, resulting in 3,750,000 additional units issued at $10 each. This increases the total units issued to 28,750,000 and total funds raised to $287,500,000 for the trust account. Starting May 7, 2021, IPO unit holders can separately trade Class A common stock and redeemable warrants under the tickers GAMC and GAMCW, respectively, while the units continue trading under GAMCU. The offering was managed by BTIG, LLC and I-Bankers Securities, Inc.
Golden Arrow Merger Corp. has successfully completed its initial public offering (IPO) of 25 million units at $10 each, raising a total of $250 million in gross proceeds. The units, consisting of one share of Class A common stock and one-third of a redeemable warrant, will trade on Nasdaq under the symbol ‘GAMCU’. Following the separation of units, the shares will trade under ‘GAMC’ and the warrants under ‘GAMCW’. The company intends to pursue a merger or acquisition, focusing on the healthcare sector. BTIG, LLC was the sole book-running manager for the offering.
Golden Arrow Merger Corp. announced the pricing of its initial public offering (IPO) of 25 million units at $10.00 each, expected to start trading on Nasdaq under the symbol GAMCU on March 17, 2021. Each unit comprises one share of Class A common stock and one-third of a redeemable warrant, with each whole warrant allowing purchase of a share at $11.50. The offering is set to close on March 19, 2021, and includes a 45-day option for underwriters to purchase additional units. The company is focused on healthcare-related business opportunities.
FAQ
What is the market cap of Golden Arrow Merger (GAMC)?
